Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 9039 results

  1. Asunercept for treating glioblastoma [ID1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC

  2. Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

    In development Reference number: GID-TA10542 Expected publication date: TBC

  3. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development Reference number: GID-TA10573 Expected publication date: TBC

  4. Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

    In development Reference number: GID-TA10497 Expected publication date: TBC

  5. Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

    In development Reference number: GID-TA10249 Expected publication date: TBC

  6. Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]

    In development Reference number: GID-TA10313 Expected publication date: TBC

  7. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

  8. Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]

    In development Reference number: GID-TA11553 Expected publication date: TBC

  9. Camlipixant for treating refractory or unexplained chronic cough [ID6722]

    Awaiting development Reference number: GID-TA11707 Expected publication date: TBC

  10. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date:  23 July 2026

  11. Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]

    Awaiting development Reference number: GID-TA11892 Expected publication date: TBC

  12. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

    In development Reference number: GID-TA11613 Expected publication date: TBC

  13. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  17 September 2026

  14. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    In development Reference number: GID-NG10434 Expected publication date:  27 July 2027

  15. Tislelizumab with platinum-based chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer at high risk of recurrence [ID6708]

    Awaiting development Reference number: GID-TA11953 Expected publication date: TBC